Phoenix Biotech Acquisition - Units (1 Ord Class A & 1/2 War) EBIT

The latest EBIT for PBAXU is $-17M as of June 2026. That compares with $-23M in the prior-year period — up 23.9% year over year. That is above the sector sector average of $-18M. Investors often review this figure alongside Phoenix Biotech Acquisition - Units (1 Ord Class A & 1/2 War)'s historical trend and sector peers before judging valuation or financial health.

Over the past year, PBAXU's EBIT moved from $-23M to $-17M — a 23.9% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Phoenix Biotech Acquisition - Units (1 Ord Class A & 1/2 War)'s operating scale or balance-sheet position.

Against its sector companies, PBAXU currently prints $-17M for EBIT, while the sector average sits near $-18M. That is roughly 0.8% above the sector mean. Large gaps often invite a closer look at Phoenix Biotech Acquisition - Units (1 Ord Class A & 1/2 War)'s growth, margins, and balance sheet.

A EBIT figure of $-17M for PBAXU is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $-18M. Explore the charts below for those layers of context.

After noting PBAXU's EBIT ($-17M), review year-over-year change from $-23M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.